Dexamethasone Implant
Simultaneous Intravitreal Ranibizumab and Dexamethasone Implant Administration at the Same Setting in Eyes with Severe Diabetic Macular Edema
... and dexamethasone implant ad- ministration at the same setting as the first treatment ...and dexamethasone implant were simulta- neously employed at the same setting as the first treatment ...
7
<p>Dexamethasone implant in the management of diabetic macular edema from clinician’s perspective</p>
... of dexamethasone implant in patients with diabetic macular edema ...junctions. Dexamethasone intravitreal implant has demonstrated ef fi cacy in the treatment of DME resistant to anti-VEGF ...
12
Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema
... mg dexamethasone implant is consistently more efficacious than the ...dexamethasone implant. The response to treatment with the 0.7 mg dexamethasone implant lasts for up to 180 ...
8
Intravitreal dexamethasone implant versus triamcinolone acetonide for macular oedema of central retinal vein occlusion: quantifying efficacy and safety
... for dexamethasone- implant, GENEVA [7] study reported that 15% study eyes showed IOP elevation of at-least 25 mmHg peaking at day 60 and normalising by day ...
8
Risk factors for and management of anterior chamber intravitreal dexamethasone implant migration
... A 47-year-old woman with noninfectious chronic uveitis and persistent cystoid macular edema (CME) was referred to our institution due to a dislocated IOL in the vitreous chamber in August 2010. A vitrectomy was ...
7
Retrospective, controlled observational case study of patients with central retinal vein occlusion and initially low visual acuity treated with an intravitreal dexamethasone implant
... DEX implant: Dexamethasone implant; EMA: European medicines agency; ETDRS: Early treatment diabetic retinopathy study; FA: Fluorescein angiography; IOP: Intraocular pressure; ME: Macular edema; RVO: ...
8
<p>Real Life Experience of Dexamethasone Implant in Refractory Diabetic Macular Oedema</p>
... The age, gender, type of DM, previous ocular surgeries and treatments were checked. The intraocular pressure (IOP) was measured with Goldmann applanation tonometry (Haag-Streit, Bern, Switzerland). The OCT images were ...
8
Intravitreal dexamethasone implant Ozurdex® in naïve and refractory patients with different subtypes of diabetic macular edema
... intravitreal dexamethasone implant (Ozurdex) is effective for the treatment of diabetic macular edema, even in refractory cases that have failed to respond to previous ...
8
Therapeutic effect of dexamethasone implant in retinal vein occlusions resistant to anti-VEGF therapy
... Our study is limited by its size; with only ten patients, strong conclusions are difficult to establish. In addition, the failure of a positive response in one of our primary outcomes, MP, is another limitation. Given ...
8
<p>Efficacy and Safety of Combined Vitrectomy with Intravitreal Dexamethasone Implant for Advanced Stage Epiretinal Membrane</p>
... The data about the intraoperative use of DXI are contro- versial. In a case – control study, intraoperative intravitreal cor- ticosteroids, both DXI and triamcinolone acetonide, showed to accelerate the normalization of ...
8
Acuity and colour vision changes post intravitreal dexamethasone implant injection in patients with diabetic macular oedema
... The dexamethasone intravi- treal implant—Ozurdex (Allergan ...biodegradable implant made of polyacticglycolic acid matrix, containing dexamethasone that is injected into the vitreous through ...
15
Intravitreal dexamethasone implant for central retinal vein occlusion without macular edema
... In the treatment of CRVO with ME, the GENEVA study [15] revealed that intravitreal steroid therapy could significantly improve ME and visual outcomes. However, for CRVO patients without ME complaining of severely ...
11
Dexamethasone implant in silicone oil: in vitro behavior
... DEX implant inside a human ...intravitreal implant in the presence of a pro-inflammatory enzyme rich environ- ment at the posterior segment of the eye that contrib- ute to the rapid disintegration of the ...
9
Widening use of dexamethasone implant for the treatment of macular edema
... mg dexamethasone (DEX) implant is approved in Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious ...
14
Ozurdex® (a slow release dexamethasone implant) in proliferative vitreoretinopathy: study protocol for a randomised controlled trial
... Ozurdex W is an intravitreal implant containing 700 μg of dexamethasone in a slow-release preparation. It is indicated for the treatment of adult patients with macula oedema following retinal vein occlusion ...
8
Dexamethasone intravitreal implant for the treatment of noninfectious uveitis
... with dexamethasone implant (either ...mg dexamethasone implant, the 0.35 mg implant, and the sham group, ...the dexamethasone treated eyes than the sham group throughout the ...
9
← Return to Article Details Alternative treatment methods in eyes with pseudophakic cystoid macular edema Download
... at 12 months. Landré et al (23) reported a significant improvemed in term of macular edema treatment in which the mean central foveal thickness decreased from 598 μm. to 286 μm at month 1, 338 μm at month 3, and was 441 ...
6
Efficacy and safety of different doses of a slow-release corticosteroid implant for macular edema: meta-analysis of randomized controlled trials
... The dexamethasone implant may be of value in vitrectomized eyes, where anti-VEGF has shown a significantly shorter half-life compared with nonvitrectomized eyes in previous reports, 25 although some authors ...
9
A 6-month, subject-masked, randomized controlled study to assess efficacy of dexamethasone as an adjunct to bevacizumab compared with bevacizumab alone in the treatment of patients with macular edema due to central or branch retinal vein occlusion
... the dexamethasone implant decreases the median number of required anti-VEGF injections over a 6 month ...+ dexamethasone) needed to produce an optimal treatment ...
8
<p>Adding a Corticosteroid or Switching to Another Anti-VEGF in Insufficiently Responsive Wet Age-Related Macular Degeneration</p>
... 0.7mg Dexamethasone implant (Ozurdex ® Allergan Pharmaceuticals, Westport, Ireland) within 6 weeks of their last anti-VEGF injection or 50 µL (corresponding to an estimated equivalent of 4 mg) of crys- ...
7